Table A3.
Outcomes according to subgroups in the second-line setting.
| Trial ID | Tumor Type | PD-L1 Status | N | Arm A | Arm B | HR OS (95% CI) | HR PFS (95% CI) | SAE A | SAE B |
|---|---|---|---|---|---|---|---|---|---|
| KEYNOTE-061 | G/GEJ | CPS ≥ 1 | 395 | Pembrolizumab | Chemo | 0.82 (0.66–1.03) | 1.27 (1.03–1.57) | NA | NA |
| G/GEJ | All | 592 | Pembrolizumab | Chemo | 0.94 (0.79–1.12) | 1.49 (1.25–1.77) | 42 (0.14) | 96 (0.35) | |
| G/GEJ | CPS ≥ 10 | 197 | Pembrolizumab | Chemo | 2.05 (1.5–2.79) | NA | NA | NA | |
| ATTRACTION-3 | ESCC | All | 419 | Nivolumab | Chemo | 0.77 (0.62−0·96) | 1.08 (0.87–1.34) | 38 (0.18) | 133 (0.65) |
| ESCC | PD-L1 ≥ 1% | 203 | Nivolumab | Chemo | 0.69 (0.51−0·94) | NA | 38 (0.18) | 133 (0.65) | |
| KEYNOTE-181 | EAC/ESCC | All | 628 | Pembrolizumab | Chemo | 0.89 (0.75–1.05) | 1.11 (0.94–1.31) | 57 (0.182) | 121 (0.49) |
| EAC/ESCC | CPS ≥ 10 | 222 | Pembrolizumab | Chemo | 0.69 (0.52–0.93) | 0.73 (0.54–0.97) | NA | NA | |
| ESCC | All | 401 | Pembrolizumab | Chemo | 0.78 (0.63–0.96) | 0.92 (0.75–1.13) | NA | NA | |
| ESCORT | ESCC | All | 448 | Camrelizumab | Chemo | 0.71(0.57–0.87) | 0.69 (0.56–0.86) | 44 (0.193) | 87 (0.395) |
| ESCC | CPS ≥ 1% | 191 | Camrelizumab | Chemo | 0.58 (0.42–0.81) | NA | 44 (0.193) | 87 (0.395) |